SuperworthCore Laboratories CLB
- Market cap
- $454.7M
- PE
- 19.1×
- 3y median 22.8×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.9×
- EV/EBIT
- 11.5×
- Revenue, 12 months
- $519.2M
- +0% on a year ago
- Net margin
- 4.7%
- Free cash flow yield
- 3.3%
Core Laboratories trades at 19.1× trailing earnings, cheaper than 84% of the last ten years. Revenue was $519.2M over the last twelve months, up 0% on a year earlier with a 5% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $125.3M−1% | $128.2M+1% | $129.6M+1% | $130.6M+2% | $134.4M+7% | $129.2M+1% | $123.6M−5% | $130.2M−0% | $134.5M+0% | $138.3M+7% | $121.8M−1% | $124.6M−4% | |
| Cost of revenue | $96.6M−2% | $101.5M+2% | $104.6M+3% | $102.9M+3% | $106.8M+11% | $106.2M+5% | $99.5M−5% | $103.7M+1% | $104.9M−2% | $109.5M+3% | $102.1M+3% | $101.4M−2% |
| Gross profit | $28.7M+6% | $26.7M−4% | $25M−7% | $27.6M+0% | $27.6M−4% | $23M−14% | $24.1M−4% | $26.5M−4% | $29.6M+7% | $28.7M+25% | $19.7M−18% | $23.2M−12% |
| $14.7M+0% | $14.6M−7% | $8.6M+32% | $16M−15% | $19.8M+35% | $14.2M−3% | $4.4M−49% | $15.3M−5% | $20.9M+6% | $15.8M+12% | $1.9M−57% | $9.2M−40% | |
| Interest expense | $3.1M+0% | $3.6M+17% | $3.4M−0% | $3.2M−1% | $3.1M−1% | $2.6M−27% | $2.6M−24% | $2.7M−16% | $2.6M−15% | $2.6M−1% | $2.9M+11% | $2.8M+5% |
| Pre-tax income | $11.5M+0% | $11M−13% | $5.1M+69% | $12.8M−18% | $16.7M+45% | $11.5M+5% | $1.8M−65% | $12.6M−2% | $18.3M+10% | $13.2M+15% | −$1M | $6.3M−50% |
| $2.3M−40% | $159K−97% | $1.7M+172% | $3.6M | $4.7M+104% | $4.1M+2464% | $1.7M+5% | $1.9M−47% | $3.8M−20% | $8.1M+99% | −$251K | $507K−74% | |
| Net income | $9.3M+23% | $2.2M−67% | $3.2M+36% | $9M−61% | $11.7M+27% | $7.4M+237% | −$154K | $10.6M+18% | $14.2M+21% | $4.9M−33% | −$789K+412% | $6M−44% |
| $0.19+19% | $0.05−67% | $0.07+40% | $0.19−60% | $0.25+32% | $0.16+220% | $0.00 | $0.22+16% | $0.30+20% | $0.11−31% | −$0.02 | $0.13−41% | |
| 47.6M+1% | 47.5M+3% | 47.7M+1% | 47.7M+1% | 47.8M+1% | 47.7M+0% | 46.8M−2% | 47.4M−1% | 47.1M−2% | 46M−4% | 46.1M−2% | 46.9M−1% |
Revenue: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them. 16 periods, Q2 FY22 to Q2 FY26: not printed by the filing, worked out from its own lines.
Operating income: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Income tax: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
Net income: Q1 FY22 and Q1 FY23: 6 months less the 3 months printed beside them.
EPS, diluted: 6 periods, Q1 FY22 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY22: share-days: the 6-month average less the second quarter's. 4 periods, Q4 FY22 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Oil & Gas Equipment & Services nearest Core Laboratories' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CLBCore Laboratories | $454.7M | 19.1× | 22.8× | 0.9× | +0% | 4.7% | |
| NGSNatural Gas Services | $399.5M | 19.2× | 25.6× | 2.1× | +15% | 10.8% | |
| RNGRRanger Energy Services | $344.2M | 24.5× | 16.6× | 0.6× | +6% | 2.4% | |
| HOSHornbeck Offshore Services | $1B | 26.3× | 7.3× | 0.8× | +6% | 3.0% | |
| RESRPC | $1.4B | 69.4× | 14.2× | 0.8× | +25% | 1.3% | |
| TUSKMammoth Energy Services | $128.5M | 134× | 13.6× | n/m | n/m | n/m | |
| INVXInnovex International | $2.1B | 33.6× | 20.1× | 2.1× | +15% | 6.2% | |
| LBRTLiberty Energy | $2.5B | 65.0× | 8.8× | 0.6× | +14% | 0.9% | |
| OIIOceaneering International | $3.9B | 11.9× | 21.2× | 1.3× | +3% | 11.4% | |
| SEISolaris Energy Infrastructure | $4.5B | 68.3× | 13.3× | 5.9× | +71% | 7.2% | |
| Peer median | $1.4B | 33.6× | 14.2× | 1.1× | +14% | 4.6% |
More on Core Laboratories
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #3of 21Oilfield services stocks with the lowest EV/EBIT
- #5of 17Oilfield services stocks with the lowest PE ratio
- #7of 15Oilfield services stocks with the fastest earnings growth
Its groups
About
- Industry
- Oil & Gas Equipment & Services
- Sector
- Energy
Valuation data, not investment advice. Prices as of .